Portrait photo of Paul Boutros

Paul Boutros, PhD, MBA, is a professor and director of the NCI-designated cancer center at Sanford Burnham Prebys Medical Discovery Institute.

Image credit: Sanford Burnham Prebys 

Paul C. Boutros, PhD, MBA, is a professor and director of the National Cancer Institute-designated cancer center at Sanford Burnham Prebys Medical Discovery Institute. In previous research, he and colleagues had discovered that permanent changes in prostate cancer DNA, called somatic mutations, shape the aggressiveness of cancers. 

But this discovery led to a major new question: How do changes in the DNA lead to changes in the cancers that affect growth rates and response to therapy? 

In a new paper, published in the journal Cancer Discovery, senior author Boutros and an international team of co-authors, identify the answer: prostate tumor methylation. 

Methylation is a fundamental process in cell biology that involves chemical tags called methyl groups being attached to specific DNA segments. The process turns certain genes on or off. In cancer, methylation can reveal how a tumor is likely to behave or respond to treatments. Because methylation changes happen to DNA after mutations occur, it serves as the key link between cancer genetics and patient outcome. 

To fully define this process, Boutros and colleagues created a compendium of 3,001 multi-ancestry prostate methylomes (a complete set of DNA methylation modifications) spanning normal tissue through localized prostate disease of all grades to advanced metastatic disease.  A subset of 884 samples also had multi-omic DNA and/or RNA characterization. Samples for this study came from around the world. 

Boutros’  team found that of the millions of potential methylation patterns in prostate cancer, four specific patterns were extremely common. These so-called “methylation subtypes” recurred across patients and closely reflected the clinical aggressiveness of cancers. One subtype was associated with normal aging prostate and extremely slow growing cancers. Two subtypes were associated with prostate cancers that tended to grow at a moderate pace, but rarely moved out of the prostate. And the final subtype almost exclusively occurred in prostate cancers that metastasized and became lethal.